View Older Stories View More Recent Stories
-
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe
-
Wolfe Research Downgrades Abbvie (ABBV) to Peerperform
-
After-hours movers: Lockheed Martin, Canadian Solar, Revolution Medicines and more
-
Abbvie: Not In Discussions With Revolution Medicines - Reuters
-
AbbVie reports $1.3 billion Q4 expense from acquired research deals
-
AbbVie in Advanced Talks to Buy Revolution Medicines - WSJ
-
UBS Assumes Abbvie (ABBV) at Neutral
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Trump to announce prescription drug price agreements
-
HSBC highlights one pharma stock to buy and one to sell for 2026
-
HSBC Upgrades Abbvie (ABBV) to Buy
-
AbbVie's SKYRIZI receives positive reimbursement nod in Canada for UC
-
Bernstein on IRA pricing: $245 really is the floor
-
FDA issues warning letters to 18 websites selling unapproved Botox products
-
Abbvie (ABBV) PT Raised to $225 at Bernstein SocGen Group
-
DZ Bank Downgrades Abbvie (ABBV) to Hold
-
Abbvie (ABBV) PT Raised to $256 at Raymond James
-
AbbVie (ABBV) Tops Q3 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance
-
Analysts expect AbbVie’s core franchises to offset R&D costs ahead of Q3 earnings
-
AbbVie (ABBV) call put ratio 1 call to 1 put into quarter results
-
AbbVie (ABBV) call put ratio 1.8 calls to 1 put into quarter results
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
Abbvie (ABBV) PT Raised to $258 at BMO Capital
-
AbbVie's RINVOQ outperforms HUMIRA in rheumatoid arthritis study
-
Abbvie (ABBV) PT Raised to $242 at Guggenheim, 'Looking for Additional Treats on Halloween to Drive Further Upside'
-
Abbvie (ABBV) PT Raised to $250 at Raymond James
-
Cantor Fitzgerald Notes IPR&D Charge Impact on Abbvie's (ABBV) 3Q EPS
-
Erste Group Downgrades Abbvie (ABBV) to Hold
-
FDA approves expanded RINVOQ indication for inflammatory bowel disease
-
Abbvie (ABBV) PT Raised to $284 at Piper Sandler
-
Abbvie (ABBV) PT raised to $250 at Cantor Fitzgerald on Skyrizi, Vyalev gains
-
Aldeyra Therapeutics (ALDX) PT Raised to $7 at Jefferies
-
AbbVie reports $2.7 billion IPR&D expense to impact Q3 earnings
-
AbbVie (ABBV) call put ratio 2.8 calls to 1 put with a focus on November 210 calls
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
AbbVie starts $70 million expansion at Massachusetts biologics facility
-
AbbVie submits FDA application for rare blood cancer treatment
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
AbbVie breaks ground on $195 million Illinois manufacturing facility
-
AbbVie sets UK price for ovarian cancer drug ELAHERE equal to US rate
-
AbbVie submits FDA application for parkinson's drug tavapadon
-
Abbvie (ABBV) PT Raised to $243 at Leerink Partners
-
Allergan Aesthetics expands SKINVIVE to 35 new markets globally
-
Raymond James: 'LinkedIn posts from executives at AbbVie indicate that the company has selected Salesforce for its future CRM'
-
Berenberg Upgrades Abbvie (ABBV) to Buy
-
Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $240 at BMO Capital
-
AbbVie (ABBV) Declares $1.64 Quarterly Dividend; 3.1% Yield
-
Raymond James Reiterates Outperform Rating on Abbvie (ABBV)
